Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas.

No abstract is available for this paper.

• Publication year

  1992

• Venue

  Archives of Surgery

• Publication date

  1992-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/ARCHSURG.1992.01420110083017PMID 1359851
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Adjuvant chemotherapy after resection of adenocarcinoma of the periampullary region and the head of the pancreas

  2004cited by this paper
• Pancreatic carcinoma.

  1992cited by this paper
• Surgical treatment of pancreatic cancer

  1991cited by this paper
• Theoretical Basis and Clinical Applications of 5-Fluorouracil as a Radiosensitizer — an Overview

  1991cited by this paper
• Adenocarcinoma of the pancreas: current management of resectable and locally advanced disease.

  1991cited by this paper
• Extended surgical resection for adenocarcinoma of the pancreas

  1991cited by this paper
• Protracted (Continuous 5-Fluorouracil) Infusion with Concomitant Radiation Therapy: Indications and Results

  1991cited by this paper
• Concomitant benefit of preoperative irradiation in preventing pancreas fistula formation after pancreatoduodenectomy.

  1991cited by this paper
• Implications of peritoneal cytology for staging of early pancreatic cancer.

  1991cited by this paper
• Effectiveness of multimodality treatment for resectable pancreatic Cancer

  1990cited by this paper
• Overview of chemotherapy for pancreatic cancer

  1990cited by this paper
• Patterns of failure after curative resection of pancreatic carcinoma

  1990cited by this paper
• Combination of intraoperative radiation with resection of Cancer of the pancreas

  1990cited by this paper
• Survival After Pancreatoduodenectomy: 118 Consecutive Resections Without an Operative Mortality

  1990cited by this paper
• Clinical and histopathological appraisal of preoperative irradiation for adenocarcinoma of the pancreatoduodenal region

  1989cited by this paper
• 5-Fluorouracil radiation sensitization — A brief review

  1989cited by this paper
• An analysis of the reduced morbidity and mortality rates after pancreaticoduodenectomy.

  1989cited by this paper
• Practical Usefulness of Lymphatic and Connective Tissue Clearance for the Carcinoma of the Pancreas Head

  1988cited by this paper
• Improved hospital morbidity, mortality, and survival after the Whipple procedure.

  1987cited by this paper
• Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.

  1985cited by this paper
• A pilot study of protracted venous infusion of 5-fluorouracil and concomitant radiation therapy.

  1985cited by this paper
• Rapid intra-abdominal spread of pancreatic cancer. Influence of multiple operative biopsy procedures.

  1985cited by this paper
• Curative surgery for adenocarcinoma of the pancreas/ampulla of Vater: the role of adjuvant pre or postoperative radiation therapy.

  1983cited by this paper
• Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-Fluorouracil or ftorafur and X rays.

  1982cited by this paper
• Phase I study of protracted venous infusion of 5‐fluorouracil

  1981cited by this paper
• Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5‐fluorouracil), and high dose radiation + 5‐fluorouracil. The gastrointestinal tumor study group

  1981cited by this paper
• Preoperative irradiation in carcinoma of the pancreas

  1980cited by this paper
• Carcinoma of the pancreas: Review of MGH experience from 1963 to 1973—Analysis of surgical failure and implications for radiation therapy

  1976cited by this paper
• Comparison of continuously infused 5‐fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma

  1975cited by this paper
• Radiobiology for the radiologist

  1973cited by this paper
• Histological Evaluation of Effects of Radiotherapy and Chemotherapy for carcinomas

  1971cited by this paper
• Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer.

  1969cited by this paper
• TREATMENT OF CARCINOMA OF THE AMPULLA OF VATER.

  1935cited by this paper

• Real-world oncological and pathological outcomes after neoadjuvant chemotherapy with gemcitabine plus S-1 for resectable pancreatic cancer: A propensity score-matched cohort study.

  2026cites this paper
• Outcomes of conversion surgery for patients with locally advanced pancreatic cancer under strict indication criteria.

  2026cites this paper
• Relative Dose Intensity and Outcomes in Elderly Patients With Resectable Pancreatic Cancer Receiving Neoadjuvant Chemotherapy.

  2026cites this paper
• Updates on Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Adenocarcinoma.

  2026cites this paper
• Neoadjuvant Therapy-Induced Remodeling in Pancreatic Ductal Adenocarcinoma: Multimodal Spatial Analysis and Prognosis.

  2026cites this paper
• Pan-tumor harmonization of pathologic response assessment for standardized data collection in neoadjuvant trials (PATHdata): Results of a Society for Immunotherapy of Cancer multi-institutional reproducibility study.

  2026cites this paper
• Complete Pathological Response to Neoadjuvant Treatment in Pancreatic Ductal Adenocarcinoma—Can We Achieve a Long-Term Survival? A Narrative Review

  2025cites this paper
• Acinar cell scoring on histology of the pancreatic stump reinforces subjective texture assessment during pancreatoduodenectomy to predict post-operative pancreatic Fistula.

  2025cites this paper
• Optimizing surgical indication in patients with borderline resectable pancreatic ductal adenocarcinoma to prevent futile pancreatectomy.

  2025cites this paper
• Updates and Review of Neoadjuvant Therapy for Resectable Pancreatic Cancer.

  2025cites this paper
• Gemcitabine-induced neutrophil extracellular traps via interleukin-8-CXCR1/2 pathway promote chemoresistance in pancreatic cancer

  2025cites this paper
• Discrepancy Between Radiographic and Pathological Response Assessment in Neoadjuvant Treatment for Pancreatic Cancer: A Comparison Between Neoadjuvant Chemotherapy and Neoadjuvant Chemoradiotherapy

  2025cites this paper
• Histopathological and genetic landscape of pancreatic ductal adenocarcinoma and its variants.

  2025cites this paper
• Endoscopic biliary drainage with multi-hole self-expandable metallic stent during neoadjuvant chemoradiotherapy in pancreatic cancer

  2025cites this paper
• Association Between the Degree of Arterial Contact Angle and Survival in Patients With Borderline Resectable Pancreatic Cancer

  2025cites this paper
• Neoadjuvant Chemoradiotherapy Using Moderately Hypofractionated Intensity-Modulated Radiotherapy Versus Upfront Surgery for Resectable Pancreatic Cancer: A Retrospective Cohort Study

  2025cites this paper
• Exploring the role of CA 19-9 dynamics in pancreatic cancer multidisciplinary treatment: Proposal of the PANC classification.

  2025cites this paper
• Neoadjuvant chemoradiotherapy using moderately hypofractionated intensity-modulated radiotherapy for borderline resectable pancreatic cancer

  2025cites this paper
• Total lesion glycolysis is a promising predictor of chemo‐response in pancreatic cancer patients treated with neoadjuvant chemotherapy prior to surgery

  2025cites this paper
• Impact of Neoadjuvant Chemotherapy with Gemcitabine Plus S-1 in Patients with Resectable Pancreatic Ductal Adenocarcinoma

  2025cites this paper
• Predicting pathological response to neoadjuvant chemoradiotherapy in resectable and borderline resectable pancreatic ductal adenocarcinoma: a comparative study of 18F-FLT and 18F-FDG PET

  2025cites this paper
• Comparative Prognostic Roles of β-Catenin Expression and Tumor–Stroma Ratio in Pancreatic Cancer: Neoadjuvant Chemotherapy vs. Upfront Surgery

  2025cites this paper
• The effect of neoadjuvant chemoradiation therapy in resectable pancreatic cancer was independent of intratumoral vascularization

  2025cites this paper
• Gadoxetic acid-enhanced magnetic resonance imaging to predict pathologic complete response of colorectal liver metastases in preoperative chemotherapy

  2025cites this paper
• Surgical outcomes of histopathological stage I pancreatic cancer with special reference to oncological differences between pStage I and ypStage I cases.

  2025cites this paper
• Perioperative Chemotherapy and Total Neoadjuvant Chemotherapy for Pancreatic Adenocarcinoma.

  2025cites this paper
• Neoadjuvant Stereotactic Ablative Radiotherapy in Pancreatic Ductal Adenocarcinoma: A Review of Perioperative and Long-Term Outcomes

  2025influential citation
• Long-term survival analysis based on tumor location in patients with pancreatic ductal adenocarcinoma who underwent pancreatectomy following neoadjuvant chemoradiotherapy

  2025cites this paper
• Comparison between Neoadjuvant Chemoradiotherapy and Chemotherapy for Patients with Resectable Pancreatic Cancer

  2025cites this paper
• Liver metastasis surgery followed by radical treatment for pancreatic ductal adenocarcinoma: A case report

  2025cites this paper
• A Phase II Study of Short-Course Neoadjuvant Chemoradiotherapy with Gemcitabine, S-1, and Hypofractionated Radiotherapy for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma

  2025cites this paper
• Seven-year survival with no recurrence after conversion surgery for pancreatic ductal adenocarcinoma with peritoneal metastasis treated with intraperitoneal and intravenous chemotherapy: A case report

  2025cites this paper
• Development of a deep learning-based model to evaluate changes during radiotherapy using cervical cancer digital pathology

  2025cites this paper
• Neoadjuvant Chemotherapy With Gemcitabine and S-1 Versus Upfront Surgery for Resectable Pancreatic Cancer

  2025cites this paper
• Distal pancreatectomy with celiac axis resection (DP-CAR) for pancreatic ductal adenocarcinoma in a retrospective monocentric cohort: neoadjuvant treatment and three-axis embolization of the celiac axis are key factors of success.

  2025cites this paper
• Evolving concepts in adjuvant/neoadjuvant therapy for resectable pancreas cancer

  2025cites this paper
• Survival and pathological response in pancreatic ductal adenocarcinoma after preoperative therapy with PD-1 blockade plus chemoradiotherapy followed by surgical resection

  2025cites this paper
• Comparison of radiological and pathological tools to assess response to neoadjuvant treatment in resected pancreatic ductal adenocarcinoma patients

  2025cites this paper
• Pancreatectomy with Celiac Axis Resection and Reconstruction for Locally Advanced Pancreatic Cancer

  2024cites this paper
• Reconsideration of the clinical impact of neoadjuvant therapy in resectable and borderline resectable pancreatic cancer: A dual-institution collaborative clinical study.

  2024cites this paper
• Impact of pancreatic ductal occlusion on postoperative outcomes in pancreatic head cancer patients undergoing neoadjuvant therapy

  2024influential citation
• Outcomes of patients with initially unresectable pancreatic cancer who underwent conversion surgery after FOLFIRINOX or gemcitabine plus nab‐paclitaxel chemotherapy: A multicenter retrospective cohort study (PC‐CURE‐1)

  2024cites this paper
• Regressionsgrading gastrointestinaler Tumoren

  2024cites this paper
• Benefits of neoadjuvant chemotherapy with gemcitabine plus S-1 for resectable pancreatic ductal adenocarcinoma

  2024cites this paper
• Survival Analysis of Conversion Surgery in Borderline Resectable and Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma Addressing Selection and Immortal Time Bias: A Retrospective Single-Center Study

  2024cites this paper
• Promising biomarker panel to monitor therapeutic efficacy of neoadjuvant chemotherapy in pancreatic cancer patients

  2024cites this paper
• miR-6855-5p Enhances Radioresistance and Promotes Migration of Pancreatic Cancer by Inducing Epithelial-Mesenchymal Transition via Suppressing FOXA1: Potential of Plasma Exosomal miR-6855-5p as an Indicator of Radiosensitivity in Patients with Pancreatic Cancer

  2024influential citation
• High likelihood of BRCA2 reversion mutation in pancreatic cancer post-platinum-based chemotherapy: a case study

  2024cites this paper
• Preoperative treatment response prediction for pancreatic cancer by multiple microRNAs in plasma exosomes: Optimization using machine learning and network analysis.

  2024cites this paper
• The Evolving Role of Neoadjuvant Radiation Therapy in Pancreatic Adenocarcinoma

  2024cites this paper
• Successful pancreatectomy after conversion-intended chemotherapy using gemcitabine and nab-paclitaxel for unresectable adenosquamous carcinoma of the pancreas: a case report

  2024cites this paper
• Successful intrahepatic cholangiocarcinoma conversion surgery after administration of fibroblast growth factor receptor inhibitor

  2024cites this paper
• Prognostic Impact of a Decrease in Serum Carbohydrate Antigen 19-9 Levels After Preoperative Therapy for 4 Months or More for Borderline Resectable Pancreatic Cancer Abutting Major Arteries

  2024cites this paper
• Neoadjuvant therapy with intensity‐modulated radiotherapy combined with S‐1 for borderline‐resectable pancreatic cancer

  2024cites this paper
• Evaluation of pancreatic cancer specimens for comprehensive genomic profiling

  2024cites this paper
• Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer

  2024cites this paper
• Changes in Skeletal Muscle Volume During Preoperative Chemotherapy Affect the Outcome of Pancreatic Cancer

  2024cites this paper
• Remarkable tumor shrinkage in hilar biliary cholangiocarcinoma confirmed by peroral cholangioscopy following neoadjuvant chemotherapy

  2024cites this paper
• A case of metachronous oligo-hepatic and peritoneal metastases of pancreatic cancer with a favorable outcome after conversion surgery combined with perioperative sequential chemotherapy

  2024cites this paper
• Short- and Long-Term Outcomes of Neoadjuvant Chemoradiotherapy Followed by Pancreatoduodenectomy in Elderly Patients with Resectable and Borderline Resectable Pancreatic Cancer: A Retrospective Study

  2024cites this paper
• Clinical significance and therapeutic implication of CD200 in pancreatic cancer.

  2024cites this paper
• Advancing Pancreatic Cancer Surgical Treatments and Proposal of New Approaches

  2024cites this paper
• A case of pancreatic head cancer with Trousseau’s syndrome treated with radical resection and anticoagulant therapy

  2023cites this paper
• Preoperative Therapy for Unresectable Locally Advanced Pancreatic Cancer for ≥6 Months Improves Prognosis After Pancreatectomy

  2023cites this paper
• Surgical Considerations for Neoadjuvant Therapy for Pancreatic Adenocarcinoma

  2023cites this paper
• Pathologic tumor response to neoadjuvant therapy in resected pancreatic cancer: does it affect prognosis?

  2023cites this paper
• Developments and challenges in neoadjuvant therapy for locally advanced pancreatic cancer

  2023cites this paper
• The differential effect of neoadjuvant chemotherapy and chemoradiation on nodal downstaging in pancreatic adenocarcinoma.

  2023cites this paper
• Pathologic Tumor Regression is Associated With Improved Survival in Pancreatic Cancer

  2023cites this paper
• Registration-based biomarkers for neoadjuvant treatment response of pancreatic cancer via longitudinal image registration

  2023cites this paper
• The benefits of neoadjuvant therapy for patients with resectable pancreatic cancer: an updated systematic review and meta-analysis

  2023cites this paper
• Phase I study of neoadjuvant S‐1 plus cisplatin with concurrent radiation for biliary tract cancer (Tokyo Study Group for Biliary Cancer: TOSBIC02)

  2023cites this paper
• Predicting conversion surgery in patients with locally advanced pancreatic cancer after modified FOLFIRINOX treatment.

  2023cites this paper
• Clinical Efficacy of Neoadjuvant Chemotherapy with Gemcitabine plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma Compared with Upfront Surgery

  2023cites this paper
• NESS Commentary for 2022-1245.

  2023cites this paper
• Prognosticators for Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Therapy and Pancreatectomy

  2023cites this paper
• Impact of neoadjuvant therapy on gut microbiome in patients with resectable/borderline resectable pancreatic ductal adenocarcinoma.

  2023cites this paper
• Multifunctional hybrid hydrogel for the prevention of post-surgery tumor recurrence.

  2023cites this paper
• Clinical Implications of FDG-PET in Pancreatic Ductal Adenocarcinoma Patients Treated with Neoadjuvant Therapy

  2023cites this paper
• Gastric intramural metastasis caused by needle tract seeding after preoperative fine needle aspiration for pancreatic body cancer subsequently resected by total pancreatectomy: a case report and literature review

  2023cites this paper
• A Paradigm Shifts: Neoadjuvant Therapy for Clearly Resectable Pancreatic Cancer

  2023cites this paper
• Pathological Nodal and Vascular Involvement Significantly Impacts the Recurrence Risk in Different Time Frames in Patients With Resectable and Borderline Resectable Pancreatic Cancer

  2023cites this paper
• Impact of skeletal muscle mass on the prognosis of patients undergoing neoadjuvant chemotherapy for resectable or borderline resectable pancreatic cancer

  2023cites this paper
• Impact of Recombinant Granulocyte Colony-Stimulating Factor During Neoadjuvant Therapy on Outcomes of Resected Pancreatic Cancer.

  2023cites this paper
• Reconsidering resectable oncological conditions in pancreatic tail cancer: A multicenter retrospective study on prognostic factors in pancreatic tail cancer after resection (HOPS Pt-01).

  2023cites this paper
• Diffusion-weighted imaging for determining response to neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis

  2023cites this paper
• Intrahepatic Cholangiocarcinoma with High Microsatellite Instability and Tumor Mutation Burden That Responded Significantly to Pembrolizumab but Perforated within a Short Period

  2023cites this paper
• Extracellular volume fraction determined by dual-layer spectral detector CT: Possible role in predicting the efficacy of preoperative neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma.

  2023cites this paper
• Perioperative Chemotherapy and Chemoradiotherapy for Patients With Resectable and Borderline Resectable Pancreatic Adenocarcinoma

  2023cites this paper
• A Liver-First Approach Using Ablation for Oligometastatic Pancreatic Cancer: A Report of a Successful Case

  2023cites this paper
• Synchronous double primary malignancies of the pancreatic body and extrahepatic bile duct treated with pancreatoduodenectomy and splenic artery resection following neoadjuvant chemotherapy with gemcitabine plus nab-paclitaxel: a case report

  2022cites this paper
• Radiation therapy in borderline resectable pancreatic cancer: A review.

  2022cites this paper
• Treatment strategy for pancreatic head cancer with celiac axis stenosis in pancreaticoduodenectomy: A case report and review of literature

  2022cites this paper
• Proposal for a New Pathologic Prognostic Index After Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma (PINC)

  2022cites this paper
• Prediction of local tumor control and recurrence‐free survival in patients with pancreatic cancer undergoing curative resection after neoadjuvant chemoradiotherapy

  2022cites this paper
• Conversion surgery for initially unresectable advanced biliary tract cancer treated with gemcitabine plus cisplatin combination chemotherapy: a case report and literature review

  2022cites this paper
• Efficacy of neoadjuvant chemoradiotherapy followed by pancreatic resection for older patients with resectable and borderline resectable pancreatic ductal adenocarcinoma.

  2022cites this paper
• Micro-lymph node metastasis in intrahepatic cholangiocarcinoma showing pathological complete response to primary tumor and intrahepatic metastasis treated by gemcitabine plus cisplatin chemotherapy and radical surgery

  2022cites this paper
• A case of pathological complete response with liposomal irinotecan + 5-FU/LV for unresectable locally advanced pancreatic cancer

  2022influential citation
• Outcomes of neoadjuvant gemcitabine plus S‐1 and radiation therapy for borderline resectable pancreatic cancer

  2022cites this paper